Compare Keurig Dr Pepper Inc. Common Stock (KDP) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keurig Dr Pepper Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $33.4 (market cap $44.44B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Keurig Dr Pepper Inc. Common Stock is far larger — about 12.3× Organon & Co. Common Stock's market cap, and Keurig Dr Pepper Inc. Common Stock pays the higher dividend (2.82%). Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| KDP | OGN | |
|---|---|---|
Market Cap | $44.44B | $3.62B |
Volume | 11,656,694 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $33.50 | $13.81 |
52-Week Low | $25.31 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $72.91B | $11.04B |
Dividend Yield | 2.82% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keurig Dr Pepper (KDP) trades at $32.66, down 0.27% today, with strong technical momentum showing bullish moving averages and key support at $32. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.57 beating expectations of $0.537, and maintains a healthy 49.39% gross margin. Recent news highlights the planned 2027 business split and beverage innovation pipeline as growth catalysts.
KDP presents a favorable investment case with 62% analyst buy ratings and a $37.75 consensus price target offering 15% upside. However, risks include elevated debt levels at 74.2% of market cap and potential execution challenges with the upcoming corporate restructuring. The stock's current valuation at 32.99 P/E requires continued earnings growth to justify further appreciation.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keurig Dr Pepper Inc. Common Stock
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
